46 completed, 15 recruiting, 9 active not recruiting, 6 terminated. 33 Phase 2, 21 Phase 1, 10 Not applicable, 9 Phase 3, 1 Early Phase 1.
Follow Essential Thrombocythemia: new trials by email Literature Review of Essential Thrombocythemia trials Research Report on Essential Thrombocythemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia INCA033989, Best Available Treatment - Essential Thrombocythemia | Phase 3 | Recruiting | Incyte Corporation | 426 | 2026-09-08 | 2026-10-15 |
| CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA) VerifyNow P2Y12 assay - Essential Thrombocythemia | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 50 | 2026-07-15 | 2026-06-12 | |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 78 | 2025-08-14 | 2026-09-30 |
| Efficacy and Safety of Peginterferon in ET and PV. Peginterferon α-2b injection - Essential Thrombocythemia, Polycythemia Vera | Not applicable | Recruiting | Zhenya Hong | 40 | 2024-11-20 | 2024-12-16 |
| Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET Peginterferon α-2b injection - Essential Thrombocythemia | Phase 2 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 27 | 2024-08-29 | 2025-11-17 |
| Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) Bomedemstat, Hydroxyurea, Bomedemstat placebo - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 300 | 2024-07-16 | 2026-08-27 |
| Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes Monocytes signatures in myeloproliferative neoplasms at diagnosis - Myeloproliferative Neoplasm, Polycythemia Vera | Not applicable | Recruiting | University Hospital, Angers | 70 | 2024-05-29 | 2026-08-10 |
| A Study of GLB-001 in Patients With Myeloid Malignancies GLB-001 - Polycythemia Vera, Essential Thrombocythemia | Phase 1 | Recruiting | Hangzhou GluBio Pharmaceutical Co., Ltd. | 108 | 2024-05-24 | 2025-08-19 |
| Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia | Phase 2 | Recruiting | University of Southern California | 30 | 2024-03-01 | 2026-03-27 |
| A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) Bomedemstat, Anagrelide, Busulfan - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 340 | 2023-12-31 | 2026-10-02 |
| Asian Myeloproliferative Neoplasm (MPN) Registry Myeloproliferative Neoplasm, Polycythemia Vera | Recruiting | The University of Hong Kong | 1000 | 2023-05-01 | 2023-05-31 | |
| Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm Peptide-based vaccine, Poly ICLC - Myelofibrosis, Essential Thrombocythemia | Phase 1 | Active not recruiting | Marina Kremyanskaya | 7 | 2023-04-04 | 2026-09-28 |
| A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET Ropeginterferon alfa-2b-njft (P1101) - Essential Thrombocythemia | Phase 2 | Active not recruiting | PharmaEssentia | 91 | 2022-09-29 | 2025-08-13 |
| AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms Direct Oral Anticoagulants, Low-dose aspirin - Polycythemia Vera, Essential Thrombocythemia | Phase 3 | Recruiting | University Hospital, Brest | 1308 | 2022-07-13 | 2026-03-20 |
| Ruxolitinib in Thrombocythemia and Polycythemia Vera Ruxolitinib - Essential Thrombocythemia, Polycythemia Vera | Phase 2 | Recruiting | Massachusetts General Hospital | 60 | 2022-03-21 | 2026-01-08 |
| An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms N-Acetylcysteine - Myeloproliferative Neoplasm, MPN | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 27 | 2022-01-03 | 2026-03-10 |
| Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) CALR allele burden quantification - Myeloproliferative Neoplasm, Essential Thrombocythemia | Not applicable | Recruiting | University Hospital, Angers | 260 | 2021-10-28 | 2026-03-06 |
| Two Step Haplo With Radiation Conditioning Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | Thomas Jefferson University | 63 | 2021-10-25 | 2025-10-30 |
| IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) IMG-7289 - Essential Thrombocythemia, Polycythemia Vera | Phase 2 | Active not recruiting | Terrence J Bradley, MD | 4 | 2020-10-02 | 2026-01-07 |
| Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) Bomedemstat - Essential Thrombocythemia | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 73 | 2020-09-08 | 2026-05-04 |
Showing 20 of 83. Sign in to see all of them.
Thrombocythemia, Essential (83) · Polycythemia Vera (63) · Primary Myelofibrosis (55) · Myeloproliferative Disorders (35) · Leukemia, Myelomonocytic, Chronic (20) · Leukemia, Myeloid, Acute (18) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (11) · Multiple Myeloma (11) · Congenital Abnormalities (10) · Leukemia, Myeloid, Accelerated Phase (10) · Pdgfra-Associated Chronic Eosinophilic Leukemia (10) · Hodgkin Disease (9) · Leukemia, Neutrophilic, Chronic (9)
Hemic and Lymphatic Diseases (83) · Blood Coagulation Disorders (81) · Blood Platelet Disorders (81) · Hemorrhagic Disorders (81) · Bone Marrow Diseases (80) · Hematologic Diseases (78) · Thrombocytosis (78) · Neoplasms (64) · Neoplasms by Site (64) · Bone Marrow Neoplasms (63) · Hematologic Neoplasms (60) · Myeloproliferative Disorders (48) · Neoplasms by Histologic Type (26) · Leukemia, Myeloid (25) · Pathologic Processes (25)
fludarabine phosphate (7) · Mycophenolic Acid (6) · Peripheral Blood Stem Cell Transplantation (6) · Tacrolimus (6) · Whole-Body Irradiation (6) · ruxolitinib (6) · Cyclophosphamide (4) · anagrelide (4) · bomedemstat (4) · Biopsy (3) · Busulfan (3) · Flow Cytometry (3) · Injections (3) · Specimen Handling (3) · fludarabine (3)
National Cancer Institute (NCI) (10) · Fred Hutchinson Cancer Center (6) · Icahn School of Medicine at Mount Sinai (4) · University Hospital, Angers (3) · University Hospital, Brest (3) · City of Hope Medical Center (2) · Eli Lilly and Company (2) · Hamad Medical Corporation (2) · Inge Marie Svane (2) · Merck Sharp & Dohme LLC (2) · PharmaEssentia (2) · Sierra Oncology LLC - a GSK company (2) · University of California, Irvine (2) · University of Utah (2) · AOP Orphan Pharmaceuticals AG (1)
United States (53) · France (16) · Italy (12) · Canada (10) · Germany (9) · United Kingdom (9) · Australia (8) · China (7) · Denmark (6) · Hong Kong (5) · Spain (5) · Japan (4) · Netherlands (4) · Poland (4) · South Korea (4)
Ronald Hoffman, MD (3) · Jacob H Grauslund, MD (2) · John Mascarenhas, MD (2) · Keith W Pratz (2) · Rona S Weinberg, PhD (2) · Ryotaro Nakamura (2) · Usama Gergis, MD (2) · Amy E DeZern, MD (1) · Anand A Patel (1) · Andrew Rezvani (1) · Andrew Roberts, M.D. (1) · Angela Fleischman, MD, PhD (1) · Angela G Fleischman, MD PhD (1)
PMID 29246923, PMID 32499241, PMID 18698002, PMID 20651074, PMID 22259028, PMID 24118452, PMID 24362550, PMID 24474568, PMID 25563429, PMID 25762180, PMID 26113113, PMID 26332546, PMID 26853648, PMID 27291777, PMID 28482711, PMID 28622623, PMID 28623609, PMID 29164292, PMID 29217781, PMID 29266414, PMID 29616837, PMID 29787944, PMID 30409796, PMID 30562587, PMID 30630975, PMID 31167802, PMID 31869407, PMID 32634234, PMID 32732354, PMID 33157979, PMID 33609248, PMID 33718228, PMID 35924546, PMID 36911725, PMID 37422688, PMID 37877698, PMID 40330782, PMID 41193116, PMID 41393215, PMID 41758981, PMID 42306077, PMID 42588744, PMID 42751490
P01CA108671 (4), P01CA018029 (3), P30CA015704 (3), 2023 (2), P30CA006973 (2), U01CA062491 (2), U01CA070095 (2), UM1CA186691 (2), 2018 (1), 2019 (1), N01CM17104 (1), N01CM62201 (1), P01CA015396 (1), P01CA078902 (1), P01HL036444 (1)